Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disorder in which the body's immune system mistakenly produces antibodies that attack and destroy healthy red blood cells. This results in a decrease in the number of red blood cells, which can cause anemia, fatigue, and other symptoms. The exact cause of AIHA is unknown, although it may be triggered by infections, medications, or other autoimmune conditions.
MOA of Autoimmune Hemolytic Anemia
The primary mechanism of action of autoimmune hemolytic anemia (AIHA) is the production of antibodies that attack and destroy healthy red blood cells. These antibodies are known as autoantibodies and they are produced by the body's own immune system. The autoantibodies attach to the healthy red blood cells, causing them to rupture and be destroyed. This leads to a decrease in the number of red blood cells, which can cause anemia, fatigue, and other symptoms.
Treatment of Autoimmune Hemolytic Anemia
The primary treatment for AIHA is immunosuppressive therapy, which involves the use of medications to suppress the body's immune system. This helps to reduce or stop the production of autoantibodies, allowing the body to create new healthy red blood cells. In some cases, a blood transfusion may be necessary to replace the lost red blood cells. In rare cases, surgery may be needed to remove the spleen, which has been shown to reduce the production of autoantibodies.
